Zydus Lifesciences Peer Comparison

NSE: ZYDUSLIFE | BSE: 532321

₹1,167.80

₹6.50 (0.56%)

As on 01-Sep-2026IST

Market cap

₹1,16,114 Cr

Revenue (TTM)

₹28,592 Cr

P/E Ratio

25.7

P/B Ratio

4.3

Div. Yield

0.1 %

Edit

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Market cap (₹ Cr)	1,16,114	98,312	97,479	97,741	96,836
Revenue (₹ Cr)	28,592	29,967	14,738	33,228	34,935
Net Profit (₹ Cr)	4,492.20	5,551.01	2,055.11	3,169.30	3,712.74
Net Margin (%)	14.92	18.23	13.64	9.15	10.42
RoE (%)	18.78	28.32	13.60	8.72	10.38
Price to Earnings	25.73	17.78	47.72	30.33	26.08
Price-To-Book	4.31	4.13	5.79	2.56	2.49

Income Statement (₹ Cr)

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Operating Revenue	28,591.70	29,966.58	14,737.88	33,227.90	34,935.29
Total Income	30,111.40	30,442.31	15,061.79	34,650.70	35,624.79
Total Expenditure	21,334.70	20,428.27	10,911.05	28,088.10	27,850.01
EBITDA	7,257.00	9,538.31	3,826.83	5,139.80	7,085.28
Depreciation	1,724.60	1,529.37	893.20	2,119.30	1,859.31
EBIT	5,532.40	8,008.94	2,933.63	3,020.50	5,225.97
Interest	510.20	452.37	578.61	416.30	387.88
Other Income	1,519.70	475.73	323.91	1,422.80	689.50
Exceptional Items	-534.80	-557.91	-129.75	0.00	-105.51
Profit before Tax	6,007.10	7,474.39	2,549.18	4,027.00	5,422.08
Provision for Tax	1,514.90	1,923.38	494.07	857.70	1,709.34
Profit after Tax	4,492.20	5,551.01	2,055.11	3,169.30	3,712.74

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Shareholder's Funds	27,111.40	22,448.27	16,300.34	37,891.50	37,890.97
Minority Interest	-79.70	-22.18	-24.90	38.90	1.76
Non-Current Liabilities	7,112.50	3,200.22	5,011.23	3,145.10	2,580.33
Current Liabilities	15,711.90	12,651.24	6,507.25	16,747.40	18,039.01
Total Liabilities	50,672.60	38,146.06	27,754.83	56,576.70	58,196.15

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Non-Current Assets	31,677.20	11,888.82	20,274.65	27,204.00	24,040.45
Current Assets	19,906.10	24,027.38	6,954.20	30,179.30	32,708.75
Total Assets	50,672.60	38,146.06	27,754.83	56,576.70	58,196.15
Total Debt*	11,769.50	5,910.20	6,021.78	7,734.10	7,676.20
Net Current Assets	4,194.20	11,376.14	446.95	13,431.90	14,669.74
Contingent Liabilities	989.90	1,094.02	924.77	336.14	1,358.37

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Cash From Operating Activities	2,116.60	7,334.50	3,121.29	5,673.70	5,526.37
Cash Flow from Investing Activities	-8,296.10	-3,864.59	-196.42	-6,549.30	-3,458.61
Cash from Financing Activities	5,806.90	-845.87	-2,952.69	829.00	-1,269.15
Net Cash Inflow / Outflow	-372.60	2,624.04	-27.82	-46.60	798.61

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
ROCE (%)	21.39	28.86	13.24	13.75	12.76
ROE (%)	18.78	28.32	13.60	8.72	10.38
ROA (%)	10.03	16.43	7.36	5.89	6.86
EBIT Margin (%)	19.35	26.73	19.91	9.09	14.96
Net Margin (%)	14.92	18.23	13.64	9.15	10.42
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Revenue Growth (%)	21.11	28.19	14.16	-0.87	9.09
EBIT Growth (%)	-8.99	77.03	19.45	-55.06	6.91
Net Profit Growth (%)	-3.14	49.13	8.09	-44.66	8.63
EPS Growth (%)	4.31	60.86	12.27	-43.29	11.88
Book Value Growth (%)	13.19	30.75	13.74	12.99	16.04

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Price / Earnings	23.76	16.49	45.35	30.33	25.76
Price / Book Value	4.31	4.13	5.79	2.56	2.49
Dividend Yield (%)	0.09	0.84	0.04	0.68	0.24
EV/EBITDA	16.63	9.96	26.52	19.16	13.25
Market Cap (₹ Cr)	87,643.18	1,05,737.27	82,801.75	1,04,763.81	75,689.14

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debt to Equity	0.12	0.07	0.17	0.00	0.02
Short term debt to equity ratio	0.16	0.18	0.04	0.16	0.16
Current Ratio	1.27	1.90	1.07	1.80	1.81
Quick Ratio	0.91	1.42	0.74	1.35	1.15
Interest Coverage	12.77	17.52	5.41	10.67	14.98

	Zydus Lifesciences	Lupin	Mankind Pharma	Dr. Reddy'S Labs	Aurobindo Pharma
Debtors to sales (%)	18.94	22.04	11.74	30.47	20.31
Asset Turnover	0.64	0.89	0.53	0.62	0.65
Receivable days	33.55	51.23	39.93	103.79	33.71
Inventory Days	33.80	48.93	51.78	79.94	59.32
Payable days	149.82	205.75	111.46	84.78	148.20
Cash Conversion Cycle	-82.46	-105.59	-19.75	98.95	-55.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.